UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Mylan

In a report published Monday, Bank of America Merrill Lynch reiterated its Buy rating on Mylan

, and slightly raised its price target from $29.00 to $30.00. BofA Merrill Lynch noted, “With significant acquisitions in '07, MYL transformed itself from a US-only, generic-only story into a global, diversified, vertically-integrated one. Though management's original assumptions for Dey (brands) proved optimistic, we are encouraged by revenue trends in generics and potential for margin improvements. Integration risks and high debt level are key risks, but as the only large, liquid, global generic alternative to Teva, we see MYL as a higher risk, higher reward name.” Mylan closed on Friday at $27.97.